Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Masimo Corp (MASI)

Masimo Corp (MASI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,076,271
  • Shares Outstanding, K 53,541
  • Annual Sales, $ 2,048 M
  • Annual Income, $ 81,500 K
  • EBIT $ 136 M
  • EBITDA $ 237 M
  • 60-Month Beta 1.01
  • Price/Sales 4.44
  • Price/Cash Flow 29.49
  • Price/Book 6.22

Options Overview Details

View History
  • Implied Volatility 40.84% ( -2.84%)
  • Historical Volatility 22.17%
  • IV Percentile 46%
  • IV Rank 48.05%
  • IV High 55.78% on 08/05/24
  • IV Low 27.02% on 05/17/24
  • Put/Call Vol Ratio 0.23
  • Today's Volume 100
  • Volume Avg (30-Day) 96
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 3,585
  • Open Int (30-Day) 3,072

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.42
  • Number of Estimates 5
  • High Estimate 1.44
  • Low Estimate 1.39
  • Prior Year 1.25
  • Growth Rate Est. (year over year) +13.60%

Price Performance

See More
Period Period Low Period High Performance
1-Month
163.80 +3.49%
on 11/21/24
180.97 -6.33%
on 12/16/24
+4.57 (+2.77%)
since 11/20/24
3-Month
119.73 +41.59%
on 09/23/24
180.97 -6.33%
on 12/16/24
+48.10 (+39.61%)
since 09/20/24
52-Week
101.61 +66.83%
on 08/05/24
180.97 -6.33%
on 12/16/24
+55.78 (+49.04%)
since 12/20/23

Most Recent Stories

More News
Here's Why you Should Retain Nevro Stock in Your Portfolio Now

Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its technological innovations and diversification plans regarding its product portfolio. The optimism, led by a solid third-quarter...

AXGN : 15.64 (+5.32%)
NVRO : 3.79 (+5.57%)
ARAY : 1.8500 (+3.35%)
MASI : 169.52 (-0.28%)
3 Medical Instruments Industry Stocks to Buy on the GenAI Wave

Through 2024, advancements in AI and predictive analytics rapidly revolutionized the Medical Instruments industry, driving innovation in diagnostics, patient monitoring and personalized treatment. AI-powered...

VCYT : 40.89 (+4.66%)
PEN : 242.54 (-0.40%)
MASI : 169.52 (-0.28%)
Here's Why You Should Add Glaukos Stock to Your Portfolio Now

Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern.Shares of this Zacks Rank #2 (Buy)...

AXGN : 15.64 (+5.32%)
ARAY : 1.8500 (+3.35%)
MASI : 169.52 (-0.28%)
GKOS : 150.88 (+4.97%)
HealthEquity Stock Falls Despite Q3 Earnings and Revenue Beat

HealthEquity, Inc. HQY reported adjusted earnings per share (EPS) of 78 cents in third-quarter fiscal 2025, surpassing the Zacks Consensus Estimate by 9.86%. The bottom line improved 30% on a year-over-year...

AXGN : 15.64 (+5.32%)
HQY : 94.95 (+0.20%)
ARAY : 1.8500 (+3.35%)
MASI : 169.52 (-0.28%)
Here's Why You Should Add Accuray Stock in Your Portfolio Now

Accuray Incorporated ARAY is well-poised for growth in the coming quarters, courtesy of continued robust demand for its products. The optimism, led by robust international performance in the first quarter...

AXGN : 15.64 (+5.32%)
ARAY : 1.8500 (+3.35%)
MASI : 169.52 (-0.28%)
ANGO : 8.89 (+3.61%)
Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio Now

DENTSPLY SIRONA XRAY is well-poised for growth due to its robust product portfolio and continued focus on research and development. However, forex remains a concern.Shares of this Zacks Rank #3 (Hold)...

AXGN : 15.64 (+5.32%)
ARAY : 1.8500 (+3.35%)
MASI : 169.52 (-0.28%)
XRAY : 18.70 (+1.25%)
Reasons to Retain Inari Medical Stock in Your Portfolio for Now

Inari Medical, Inc. NARI is well poised for growth on the back of a huge market opportunity for its products and its commitment to understanding the venous system. However, the company’s dependency...

AXGN : 15.64 (+5.32%)
ARAY : 1.8500 (+3.35%)
MASI : 169.52 (-0.28%)
NARI : 55.45 (+1.91%)
The Zacks Analyst Blog Highlights MACOM Technology Solutions, Masimo, Leonardo DRS, Ingredion and Carpenter

For Immediate ReleaseChicago, IL – December 2, 2024 – Zacks.com announces the list of Stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

INGR : 138.19 (-0.43%)
DRS : 32.98 (+3.22%)
CRS : 169.97 (+0.22%)
MASI : 169.52 (-0.28%)
MTSI : 135.22 (-1.25%)
Buy 5 Mid-Cap Stocks Poised to Turn Into Large Caps in 2025

U.S. stock markets have witnessed renewed momentum in 2024 after an impressive 2023. The bull run continued for the past 21 months, barring some minor fluctuations. Meanwhile, market participants are expecting...

INGR : 138.19 (-0.43%)
DRS : 32.98 (+3.22%)
CRS : 169.97 (+0.22%)
MASI : 169.52 (-0.28%)
MTSI : 135.22 (-1.25%)
Masimo: Q3 Earnings Snapshot

Masimo: Q3 Earnings Snapshot

MASI : 169.52 (-0.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Masimo Corporation develops, manufactures and markets a family of non-invasive monitoring systems. The Company has two segments: Product Revenues, Royalty & Other revenues. Within Product revenues, the company's flagship - Signal Extraction Tecgnology (SET) Pulse Oximetry - is used to monitor blood oxygen...

See More

Key Turning Points

3rd Resistance Point 179.15
2nd Resistance Point 176.21
1st Resistance Point 172.86
Last Price 169.52
1st Support Level 166.57
2nd Support Level 163.63
3rd Support Level 160.28

See More

52-Week High 180.97
Last Price 169.52
Fibonacci 61.8% 150.65
Fibonacci 50% 141.29
Fibonacci 38.2% 131.93
52-Week Low 101.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar